In PepBank now:147 peptides, 6 blends and 13 other compounds97,577 study results from 17,383 studies8,473 clinical trialsUpdated
Comparing 2 peptides · Data version 308560
Swipe sideways to see every peptide.
| Peptide | Synthetic analog Goserelin | Synthetic analog Triptorelin (Trelstar, Decapeptyl) | |
|---|---|---|---|
| Identity | |||
| Kind | Synthetic analog | Synthetic analog | |
| Area | Sexual health and hormones | Sexual health and hormones | |
| Evidence | |||
| Amount of evidence | 583 | 1,338 | |
| Evidence level | Has results from studies in people | Has results from studies in people | |
| Safety | |||
| Safety results | 122 (119 in people) | 164 (160 in people) | |
| Status | |||
| Approval | |||
| Sport (WADA) | |||
| Registered trials | 309 · 71 active108 more mention it but do not test it | 207 · 44 active104 more mention it but do not test it | |
Shared outcomes
From the regulatory data of each peptide.
The FDA label for Zoladex says: “Zoladex 3.6 mg implant: locally confined Stage T2b-T4 prostate carcinoma with flutamide and radiotherapy; palliation of advanced prostate carcinoma; endometriosis; endometrial thinning before ablation for dysfunctional uterine bleeding; palliation of advanced breast cancer in pre- and perimenopausal women”
Outcome groups with study results for at least two of these peptides. Counts include only results from studies that gave the peptide. Bar length is the number of results, on one scale. The bars show how much was studied, not how large an effect was. A peptide with more studies can look stronger here without being stronger. For results, see the randomized results above.
| Outcome group | Goserelin | Triptorelin (Trelstar, Decapeptyl) |
|---|---|---|
| Sex hormones and fertilityReproductive and sexual health | 14810741 | 782599171 |
PepBank is a research reference. Talk to a doctor before you use any peptide.
The FDA label for Trelstar says: “Treatment of advanced prostate cancer”
| Adverse eventsWhole body | 62593 | 105105 |
|---|
| Tumor growthReproductive and sexual health | 938472 | 524624 |
|---|
| Bone and jointMusculoskeletal | 3434 | 74713 |
|---|
| MortalityCardiovascular | 3838 | 1212 |
|---|
| Surgical outcomesReproductive and sexual health | 2929 | 2020 |
|---|
| Receptor activity and mechanismPharmacology | 151014 | 7425715 |
|---|
| PainWhole body | 1616 | 1414 |
|---|
| Anxiety and moodMental health and mood | 1111 | 77 |
|---|
| Body weightMetabolic and weight | 11 | 17161 |
|---|
| LipidsMetabolic and weight | 99 | 981 |
|---|
| Cancer biomarkers and prognosisCancer | 1010 | 66 |
|---|
Each analog against its native parent, residue by residue. Substitutions, non-standard residues and modifications are marked. Calculated from the two sequences.
Goserelin differs from Gonadorelin at 3 positions.
What is different
Triptorelin (Trelstar, Decapeptyl) differs from Gonadorelin at 2 positions and carries 1 added group.
What is different
Registered trials, ranked by phase (late phases first), then posted results and enrollment. Status is the registry status. Study results come from published studies. Results posted at ClinicalTrials.gov are shown on each trial page.
Top 3 of 309 trials, ranked by phase, then posted results and enrollment: 3 completed · 3 with posted results · source ClinicalTrials.gov (opens in a new tab)
Novartis Pharmaceuticals3,246 participants30 Nov 2016 to 9 Nov 2022
Breast Cancer
SWOG Cancer Research Network3,040 participantsMay 1995 to Jun 2013
Prostate Cancer
Radiation Therapy Oncology Group2,028 participantsOct 1994 to 14 May 2018
Prostate Cancer
108 more mention it but do not test it. They only measure it or name it in their text.
Top 3 of 207 trials, ranked by phase, then posted results and enrollment: 2 completed · 3 with posted results · source ClinicalTrials.gov (opens in a new tab)
ETOP IBCSG Partners Foundation3,066 participants17 Dec 2003 to 6 Nov 2024
Estrogen Receptor Positive Breast Cancer · Progesterone Receptor Positive Tumor · Recurrent Breast Carcinoma · Stage IA Breast Cancer · Stage IB Breast Cancer · Stage IIA Breast Cancer · Stage IIB Breast Cancer · Stage IIIA Breast Cancer
ETOP IBCSG Partners Foundation2,672 participants3 Nov 2003 to 23 Oct 2024
Breast Cancer
Radiation Therapy Oncology Group1,792 participantsFeb 2008 to 12 Jul 2018 (primary)
Prostate Cancer
104 more mention it but do not test it. They only measure it or name it in their text.
For each outcome that two or more peptides have results for: the best result of a single randomized trial, on the same measure (the same kind of number, the same unit). When a trial has several dose arms, the cell shows the highest dose arm. The trials differ in people, length and dose, so a gap between two cells is not proof that one peptide works better.
| Outcome | Goserelin | Triptorelin (Trelstar, Decapeptyl) |
|---|---|---|
| MortalityCancerCompared as: value in the arm that got the peptide, in % | 99.4% Overall survival · goserelin plus tamoxifen at 5 years Dose studied: monthly administration2 yearsn = 1,2822020 | 97% Survival Dose studied: 3.75 mg9 monthsn = 2842003 |
| Tumor growthCancerCompared as: value in the arm that got the peptide, in % | 64% Progression-free survival Dose studied: 10·8 mg on the first day of irradiation and 3 months latern = 7432019 | 80.5% Disease-free survival |
| Sex hormones and fertilityReproductive and sexual healthCompared as: value in the arm that got the peptide, in % | 21% Pregnancy n = 2182015 | 22.7% Pregnancy rate Placebo: 22.1% Dose studied: 0.1 mgSingle injection |
| Surgical outcomesReproductive and sexual healthCompared as: value in the arm that got the peptide, in min | 15.1 min Operating time 8 weeksn = 631996 | 10.6 min Operative time n = 1452016 |
99.4%
Overall survival · goserelin plus tamoxifen at 5 years
Dose studied: monthly administration2 yearsn = 1,2822020
97%
Survival
Dose studied: 3.75 mg9 monthsn = 2842003
The other peptides have no randomized result on the same measure, so these results cannot be set side by side.
| Outcome | Goserelin | Triptorelin (Trelstar, Decapeptyl) |
|---|---|---|
| Organ injuryReproductive and sexual healthCompared as: value in the arm that got the peptide, in % | −53% AFS score reduction · Shown as a change. The study reports a afs score reduction of this size. · goserelin at 24 weeks Dose studied: 3.6 mg every 28 days24 weeksn = 3151993 |
Control at five years: 83.7%
n = 2812015
64%
Progression-free survival
Dose studied: 10·8 mg on the first day of irradiation and 3 months latern = 7432019
80.5%
Disease-free survival
Control at five years: 83.7%
n = 2812015
21%
Pregnancy
n = 2182015
22.7%
Pregnancy rate
Placebo: 22.1%
Dose studied: 0.1 mgSingle injectionn = 3442010
15.1 min
Operating time
8 weeksn = 631996
10.6 min
Operative time
n = 1452016
No comparable result 3 randomized-trial results measure it in another way or another unit. |
| PainReproductive and sexual healthCompared as: difference from placebo, in none | No comparable result 10 randomized-trial results measure it in another way or another unit. | 1 none P value Dose studied: triptorelin depot-3.753 monthsn = 542008 |
|---|
| Body compositionMetabolic and weightCompared as: value in the arm that got the peptide, in kg | 0.37 kg Leg lean mass change Placebo group: 0.57 kg Dose studied: 3.6 mg every 4 wk12 wkn = 222006 | No comparable result 5 randomized-trial results measure it in another way or another unit. |
|---|
| Cancer biomarkers and prognosisReproductive and sexual healthCompared as: value in the arm that got the peptide, in % | 73% Five-year DFS 24 monthsn not reported2003 | No comparable result 2 randomized-trial results measure it in another way or another unit. |
|---|
| Treatment adherence and retentionReproductive and sexual healthCompared as: value in the arm that got the peptide, in % | 6.4% Withdrawal Dose studied: 3.6 mg monthly24 weeksn = 3071992 | No randomized trial result 1 result from other study designs. |
|---|
| Bone and jointEndocrine and hormonesCompared as: value in the arm that got the peptide, in % | −5.4% Bone mineral density change Dose studied: 3.6 mg every 28 days24 weeksn = 3151993 | No comparable result 16 randomized-trial results measure it in another way or another unit. |
|---|
| Adverse eventsReproductive and sexual healthCompared as: difference from placebo, in percentage points | No comparable result 43 randomized-trial results measure it in another way or another unit. | −14.7 percentage points Miscarriage rate reduction · Shown as a change. The study reports a miscarriage rate reduction of this size. Dose studied: 0.1 mg, single dosen = 1442018 |
|---|
−53%
AFS score reduction · Shown as a change. The study reports a afs score reduction of this size. · goserelin at 24 weeks
Dose studied: 3.6 mg every 28 days24 weeksn = 3151993
No comparable result
3 randomized-trial results measure it in another way or another unit.
No comparable result
10 randomized-trial results measure it in another way or another unit.
1 none
P value
Dose studied: triptorelin depot-3.753 monthsn = 542008
0.37 kg
Leg lean mass change
Placebo group: 0.57 kg
Dose studied: 3.6 mg every 4 wk12 wkn = 222006
No comparable result
5 randomized-trial results measure it in another way or another unit.
73%
Five-year DFS
24 monthsn not reported2003
No comparable result
2 randomized-trial results measure it in another way or another unit.
6.4%
Withdrawal
Dose studied: 3.6 mg monthly24 weeksn = 3071992
No randomized trial result
1 result from other study designs.
−5.4%
Bone mineral density change
Dose studied: 3.6 mg every 28 days24 weeksn = 3151993
No comparable result
16 randomized-trial results measure it in another way or another unit.
No comparable result
43 randomized-trial results measure it in another way or another unit.
−14.7 percentage points
Miscarriage rate reduction · Shown as a change. The study reports a miscarriage rate reduction of this size.
Dose studied: 0.1 mg, single dosen = 1442018